Formulation and Drug Delivery

Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.

The final drug product relies on the quality and reliability of the raw materials used in its production.

Biosimilar analytical assessments focus on demonstrating biosimilarity and interchangeability with the reference biologic.

Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.

A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.

Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.

At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.

The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

Novel delivery technologies enhance brain penetration to target neurodegenerative diseases and glioblastomas.

The use of appropriate taste-masking and appearance technologies can facilitate patient compliance.

A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.

Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.

A tidal wave of questions floats the need for more upstream automation.

Developing freeze-drying processes requires patience and deep product and process understanding.

Regulations for mRNA products are evolving as the market for mRNA expands.

The LNP success in mRNA vaccines leads to their establishment as a standard in mRNA delivery.

Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles.

Packaging and packaging line innovations are addressing the industry’s growing use of biologics.

Dr. Reddy’s has gained exclusive rights to promote and distribute Sanofi’s vaccines in India.

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

The draft guidance document provides support to sponsors with drugs in clinical development that treat the states of sporadic Alzheimer’s disease.

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.